PTG-100 is under clinical development by Protagonist Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PTG-100’s likelihood of approval (LoA) and phase transition for Celiac Disease took place on 24 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PTG-100 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PTG-100 overview

PTG-100 is under development for the treatment of celiac disease. These are disulfide rich peptides and administered orally. The development of the drug candidates are based on the disulfide rich peptides (DRP) technology. The drug candidate antagonize alpha4 beta7 integrin. It was also under development for the treatment of ulcerative colitis.

Protagonist Therapeutics overview

Protagonist Therapeutics (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. Protagonist’ product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and hematological disorders. The company has its operations in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.

Quick View PTG-100 LOA Data

Report Segments
  • Innovator
Drug Name
  • PTG-100
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.